David N. Louis, MD, is the Benjamin Castleman Professor of Pathology at Harvard Medical School (since 2006), Pathologist-in-Chief at Massachusetts General Hospital (since 2006), Chair of Pathology at Brigham and Women’s Hospital (since 2022), and inaugural Chief of Enterprise Pathology at Mass General Brigham (since 2022).  Mass General Brigham Pathology has more than 200 faculty, over 200 trainees, and about 2500 staff; performs over 60 million lab tests per year including approximately 250,000 interpretations of biopsies; and features nearly $70 million in research activity. Under Dr.  Louis’ chairmanship, the MGH department became a national leader in molecular diagnostics and pathology informatics, leading to a novel initiative in computational pathology.  Dr.  Louis’ clinical neuropathology practice and research focuses on brain tumors, particularly molecular diagnostics in glioma classification.  He has published over 300 original articles, as well as numerous reviews, chapters and books (h-index = 121).  His group first demonstrated that molecular approaches could subdivide malignant gliomas and predict the therapeutic response of specific malignant gliomas, leading to worldwide adoption of molecular testing for glioma patient management.  Dr.  Louis served on the 2000 WHO Committee on the Classification of CNS Tumors; co-chaired and was the primary editor for both the 2007 and 2016 WHO classifications; and was on the expert panel for the 2021 WHO classification.  Dr. Louis chaired the CNS committee for the International Collaboration on Cancer Reporting and was the founder and inaugural chair for cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy).